To include your compound in the COVID-19 Resource Center, submit it here.

Medivation, Pfizer discontinue Dimebon in HD

Medivation Inc. (NASDAQ:MDVN) and Pfizer Inc. (NYSE:PFE) discontinued development of Dimebon latrepirdine to treat Huntington's disease (HD) after Dimebon

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE